8 Results for "

tumor shrinkage

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "tumor shrinkage" in MCE Product Catalog:

6
6 Publications Verification
Cat. No.: HY-145928
CAS No.: 2417987-45-0
Purity:  99.31%
Synonyms: GDC-6036
Target:  

Ras

Research Areas:  

Cancer

Divarasib (GDC-6036) is an orally active, selective KRAS G12C inhibitor with an IC50 of <0.01 μM. Divarasib covalently binds Cys12 in GDP-bound KRAS G12C, occupies the switch II pocket, blocks GTP binding and SOS-mediated reactivation, and inhibits oncogenic KRAS signaling. Divarasib induces tumor shrinkage and robust tumor growth inhibition in KRAS G12C-positive models and cancer cells. Divarasib can be used for the research of non-small cell lung cancer, colorectal adenocarcinoma, pancreatic ductal adenocarcinoma, and other KRAS G12C-mutated solid tumors .
loading...
    loading...
6
6 Publications Verification
Cat. No.: HY-145928B
CAS No.: 2762240-36-6
Synonyms: GDC-6036 adipate
Target:  

Ras

Research Areas:  

Cancer

Divarasib (GDC-6036) adipate is an orally active, selective KRASG12C inhibitor with an IC50 of <0.01 μM. Divarasib adipate covalently binds Cys12 in GDP-bound KRASG12C, occupies the switch II pocket, blocks GTP binding and SOS-mediated reactivation, and inhibits oncogenic KRAS signaling. Divarasib adipate induces tumor shrinkage and robust tumor growth inhibition in KRASG12C-positive models and cancer cells. Divarasib adipate can be used for the research of non-small cell lung cancer, colorectal adenocarcinoma, pancreatic ductal adenocarcinoma, and other KRASG12C-mutated solid tumors .
loading...
    loading...
Cat. No.: HY-168280
Target:  

Ligands for E3 Ligase

Research Areas:  

Cancer

AS1411-C4-VH032 (AS1411-VH032) promotes tumor-selective degradation of MDM2, leading to tumor shrinkage without detectable toxicity .
loading...
    loading...
Cat. No.: HY-117980
CAS No.: 1661-29-6
Synonyms: AB 132
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

Meturedepa (AB 132) functions as a radiation sensitizer, enhancing the biological effects of radiation. When combined with suboptimal doses of X-ray radiation, this combined therapy achieves better outcomes in terms of tumor shrinkage compared to Meturedepa used alone. Meturedepa is applicable in the research of bronchogenic carcinoma .
loading...
    loading...
Cat. No.: HY-158726
CAS No.: 2480150-28-3
Complex 3 is a fluorescent dithiocarbazate-copper complex with anticancer activity, which localizes to mitochondria. Complex 3 displays excitation/emission maxima of 455-495/535 nm, respectively. Complex 3 inhibits the growth of BxPC-3, AsPC-1, PANC-1, and WI38 pancreatic cancer cells with IC50 values of 0.74, 0.41, 0.62, and 2.06 µM, respectively. Complex 3 induces lipid peroxidation and mitochondrial rupture and shrinkage in AsPC-1 cells. Complex 3 also induces mitochondrial apoptosis and cytokine-cytokine receptor interaction dysfunction in AsPC-1 cells. Complex 3 reduces tumor volume in an AsPC-1 mouse xenograft model .
loading...
    loading...
Cat. No.: HY-119618
CAS No.: 303196-31-8
Target:  

Endogenous Metabolite

Research Areas:  

Cancer

R1498 is a multi-target kinase inhibitor with anti-angiogenic and anti-proliferative activities. R1498 mainly targets targets such as Aurora kinase and VEGFR2, which are associated with tumor development. R1498 showed moderate in vitro growth inhibition in a variety of tumor cells, with IC50 values in the micromolar range. R1498 showed anti-tumor efficacy superior to sorafenib in a variety of gastric cancer and hepatocellular carcinoma xenograft models, with tumor growth inhibition rates exceeding 80%, and tumor shrinkage was observed in some models. R1498 showed a 10-30% tumor shrinkage rate in three xenograft models derived from human primary gastric cancer tumors, further demonstrating its inhibitory potential. R1498 effectively inhibited Aurora A activity in vivo and reduced tumor vascularization .
loading...
    loading...
Cat. No.: HY-184315
CAS No.: 2411873-31-7
LDC8201 is a selective, orally active, covalent inhibitor that targets EGFR and Her2 exon 20 insertion mutants. LDC8201 induces tumor shrinkage and regression. LDC8201 is applicable to research related to non-small cell lung cancer carrying EGFR or Her2 exon 20 insertion mutations .
loading...
    loading...
Cat. No.: HY-18957C
CAS No.: 2025320-97-0
Synonyms: BGB-283 hydrochloride
Target:  

Endogenous Metabolite

Research Areas:  

Cancer

Lifirafenib hydrochloride (BGB-283 hydrochloride) is a novel, reversible B-RAFV600E inhibitor with antitumor activity. Lifirafenib has shown potent antitumor activity against solid tumors with B-RAFV600E mutations, such as melanoma, thyroid cancer, and low-grade serous ovarian cancer. Lifirafenib exhibits selective cytotoxicity in vitro, preferentially inhibiting the proliferation of cancer cells with B-RAFV600E and EGFR mutations/amplification. Lifirafenib can achieve dose-dependent inhibition of tumor growth in animal models, accompanied by partial and complete tumor shrinkage .
loading...
    loading...